Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in chinese patients: A retrospective study

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 6, 2013, Pages 3779-3784

  Li, Chun Yan ^a,b,c   Zhang, Sheng ^a,b,c   Zhang, Xiao Bei ^a,b,c   Wang, Pei ^a,b,c   Hou, Guo Fang ^a,b,c   Zhang, Jin ^a,b,c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

Age at onset; Breast cancer; Grade; Lymph node metastasis; Prognosis; Triple negative

Indexed keywords

EID: 84882575224     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.6.3779     Document Type: Article

References (35)

1. Albergaria A, Ricardo S, Milanezi F, et al (2011). Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?. BMC Cancer, 11, 299.
2. Bertucci F, Finetti P, Birnbaum D (2012). Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med, 12, 96-110.
3. Blows FM, Driver KE, Schmidt MK, et al (2010). Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med, 7, e1000279.
4. Carey LA, Dees EC, Sawyer L, et al (2007). The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res, 13, 2329-34.
5. Carey LA, Perou CM, Livasy CA, et al (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295, 2492-502.
6. Clarke MJ, WITHDRAWN (2008). Ovarian ablation for early breast cancer. Cochrane Database Syst Rev, 4, CD000485.
7. Dent R, Trudeau M, Pritchard KI, et al (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res, 13, 4429-34.
8. DeSantis C, Siegel R, Bandi P, Jemal A (2011). Breast cancer statistics, 2011. CA Cancer J Clin, 61, 409-18.
9. Furberg H, Millikan R, Dressler L, Newman B, Geradts J (2001). Tumor characteristics in African American and white women. Breast Cancer Res Treat, 68, 33-43.
10. Ghafoor A, Jemal A, Ward E, et al (2003). Trends in breast cancer by race and ethnicity. CA Cancer J Clin, 53, 342-55.
11. Gluz O, Liedtke C, Gottschalk N, et al (2009). Triple-negative breast cancer--current status and future directions. Ann Oncol, 20, 1913-27.
12. Haffty BG, Yang Q, Reiss M, et al (2006). Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol, 24, 5652-7.
13. Hudis CA, Gianni L (2011). Triple-negative breast cancer: an unmet medical need. Oncologist, 16, 1-11.
14. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
15. Kandel M, Stadler, Z, Masciari, S., et al (2006). Prevalence of BRCA1 mutations in triple negative breast cancer (BC). J Clin Oncol, 24, 508.
16. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP (2004). The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst, 96, 1659-68.
17. Livasy CA, Karaca G, Nanda R, et al (2006). Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol, 19, 264-71.
18. Menashe I, Anderson WF, Jatoi I, Rosenberg PS (2009). Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis. J Natl Cancer Inst, 101, 993-1000.
19. Minn AJ, Gupta GP, Siegel PM, et al (2005). Genes that mediate breast cancer metastasis to lung. Nature, 436, 518-24.
20. Oakman C, Moretti E, Pacini G, Santarpia L, Di Leo A (2011). Triple negative breast cancer: a heterogeneous subgroup defined by what it is not. Eur J Cancer, 47, S370-2.
21. Peddi PF, Ellis MJ, Ma C (2012). Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer, 2012, 217185.
22. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353, 1659-72.
23. Rakha EA, El-Sayed ME, Green AR, et al (2007). Prognostic markers in triple-negative breast cancer. Cancer, 109, 25-32.
24. Ray M, Polite BN (2010). Triple-negative breast cancers: a view from 10,000 feet. Cancer J, 16, 17-22.
25. Romond EH, Perez EA, Bryant J, et al (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353, 1673-84.
26. Rouzier R, Perou CM, Symmans WF, et al (2005). Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res, 11, 5678-85.
27. Siziopikou KP, Cobleigh M (2007). The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast, 16, 104-7.
28. Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A, 98, 10869-74.
29. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, et al (2000). Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol, 18, 4053-9.
30. Tischkowitz M, Brunet JS, Begin LR, et al (2007). Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer, 7, 134.
31. Trivers KF, Lund MJ, Porter PL, et al (2009). The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control, 20, 1071-82.
32. Wolff AC, Hammond ME, Schwartz JN, et al (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol, 25, 118-45.
33. Yuan ZY, Wang SS, Gao Y, et al (2008). Clinical characteristics and prognosis of triple-negative breast cancer: a report of 305 cases. Ai Zheng, 27, 561-65.
34. Yuli C, Shao N, Rao R, et al (2007). BRCA1a has antitumor activity in TN breast, ovarian and prostate cancers. Oncogene, 26, 6031-7.
35. Zhao P, Dai M, Chen W, Li N (2010). Cancer trends in China. Jpn J Clin Oncol, 40, 281-5.